Discovery and Optimization of 2-Amino-4-methylquinazoline Derivatives as Highly Potent Phosphatidylinositol 3-Kinase Inhibitors for Cancer Treatment

被引:37
作者
Lin, Songwen [1 ,2 ,3 ]
Wang, Chunyang [1 ,2 ]
Ji, Ming [1 ,2 ]
Wu, Deyu [1 ,2 ,3 ]
Lv, Yuanhao [1 ,2 ]
Zhang, Kehui [1 ,2 ,3 ]
Dong, Yi [1 ,2 ,3 ]
Jin, Jing [1 ,2 ]
Chen, Jiajing [1 ,2 ,3 ]
Zhang, Jingbo [1 ,2 ,3 ]
Sheng, Li [2 ,4 ]
Li, Yan [2 ,4 ]
Chen, Xiaoguang [1 ,2 ]
Xu, Heng [1 ,2 ,3 ]
机构
[1] Chinese Acad Med Sci, Inst Mat Med, State Key Lab Bioact Subst & Funct Nat Med, Beijing 100050, Peoples R China
[2] Peking Union Med Coll, Beijing 100050, Peoples R China
[3] Chinese Acad Med Sci, Inst Mat Med, Beijing Key Lab Act Subst Discovery & Druggabil E, Beijing 100050, Peoples R China
[4] Chinese Acad Med Sci, Beijing Key Lab Nonclin Drug Metab & PK PD Study, Beijing 100050, Peoples R China
基金
国家重点研发计划;
关键词
BRAIN-PENETRANT; CLASS-I; CLINICAL DEVELOPMENT; PATHWAY ALTERATIONS; PI3K; IDENTIFICATION; GROWTH; CANDIDATE;
D O I
10.1021/acs.jmedchem.8b00416
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Increased phosphatidylinositol 3-kinase (PI3K) signaling is among the most common alterations in cancer, spurring intensive efforts to develop new cancer therapeutics that target this pathway. In this work, we discovered a series of novel 2-amino-4-methylquinazoline derivatives through a hybridization and subsequent scaffold hopping approach that were highly potent class I PI3K inhibitors. Lead optimization resulted in several promising compounds (e.g., 19, 20, 37, and 43) with nanomolar PI3K potencies, prominent antiproliferative activities, favorable PK profiles, and robust in vivo antitumor efficacies. More interestingly, compared with 19 and 20, 37 and 43 demonstrated improved brain penetration and in vivo efficacy in an orthotopic glioblastoma xenograft model. Furthermore, preliminary safety assessments including hERG channel inhibition, AMES, CYP450 inhibition, and single-dose toxicity were performed to characterize their toxicological properties.
引用
收藏
页码:6087 / 6109
页数:23
相关论文
共 38 条
[31]   Protein kinase B kinases that mediate phosphatidylinositol 3,4,5-trisphosphate-dependent activation of protein kinase B [J].
Stephens, L ;
Anderson, K ;
Stokoe, D ;
Erdjument-Bromage, H ;
Painter, GF ;
Holmes, AB ;
Gaffney, PRJ ;
Reese, CB ;
McCormick, F ;
Tempst, P ;
Coadwell, J ;
Hawkins, PT .
SCIENCE, 1998, 279 (5351) :710-714
[32]   PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting [J].
Thorpe, Lauren M. ;
Yuzugullu, Haluk ;
Zhao, Jean J. .
NATURE REVIEWS CANCER, 2015, 15 (01) :7-24
[33]   Molecular properties that influence the oral bioavailability of drug candidates [J].
Veber, DF ;
Johnson, SR ;
Cheng, HY ;
Smith, BR ;
Ward, KW ;
Kopple, KD .
JOURNAL OF MEDICINAL CHEMISTRY, 2002, 45 (12) :2615-2623
[34]   The phosphatidylinositol 3-kinase-AKT pathway in human cancer [J].
Vivanco, I ;
Sawyers, CL .
NATURE REVIEWS CANCER, 2002, 2 (07) :489-501
[35]   Lipophilicity in drug discovery [J].
Waring, Michael J. .
EXPERT OPINION ON DRUG DISCOVERY, 2010, 5 (03) :235-248
[36]  
Wullschleger S, 2006, CELL, V124, P471, DOI 10.1016/j.cell.2006.01.016
[37]   Drugging PI3K in cancer: refining targets and therapeutic strategies [J].
Yap, Timothy A. ;
Bjerke, Lynn ;
Clarke, Paul A. ;
Workman, Paul .
CURRENT OPINION IN PHARMACOLOGY, 2015, 23 :98-107
[38]   PI3K pathway alterations in cancer: variations on a theme [J].
Yuan, T. L. ;
Cantley, L. C. .
ONCOGENE, 2008, 27 (41) :5497-5510